In the KEYNOTE-826 trial, the addition of the PD-1 inhibitor pembrolizumab to standard-of-care chemotherapy significantly prolonged progression-free survival and overall survival in patients with metastatic, recurrent, or persistent cervical cancer. These findings could define the new standard of care in these cases.

©2021 American Association for Cancer Research.
2021
American Association for Cancer Research.
You do not currently have access to this content.